文献速递自身炎症与 IgG4 相关病

推动慢性非细菌性骨髓炎临床试验的迫切需求

Addressing the urgent need for clinical trials in chronic non-bacterial osteomyelitis.
PubMed 文献 · Lancet Rheumatol · 2026-01-01

本文为观点文章,聚焦主要累及儿童和青少年的自身炎症性骨病慢性非细菌性骨髓炎(CNO)。文章指出CNO是儿童期第二常见的炎症性风湿病,但目前尚无获批治疗药物,临床试验长期受制于缺乏经验证的分分类标准、纳入排除标准、疗效评价工具及商业市场狭小。自2022年以来分类标准、纳入排除专家共识和结局指标相继建立,文章主张采用平台试验设计对照共同对照药以加速证据生成与药物获批。

要点

  • CNO是儿童期第二常见炎症性风湿病,目前无获批治疗药物。
  • 分类标准、纳入排除专家共识与结局指标自2022年起已逐步建立。
  • 平台试验设计对照共同对照药有望为CNO药物获批提供证据。

核心结论

  • CNO临床试验虽长期受阻,但自2022年起分类标准、纳入排除标准和结局指标的建立已部分克服障碍,亟需开展试验以生成证据并实现药物获批。

研究设计与样本

  • 本文为Viewpoint观点文章,总结CNO现有治疗与有前景的候选治疗,并概述试验设计的挑战及部分已克服的途径。

主要发现

  • CNO以骨痛、骨质增生和骨畸形为特征,影响患者生活质量。
  • CNO是儿童期第二常见的炎症性风湿病,但尚无获批治疗。
  • 临床试验受阻于缺乏经验证分类标准、纳入排除标准、疗效评价工具及商业市场狭小。

关键数值与推荐

  • 自2022年以来已制定分类标准、纳入排除标准专家共识并开发结局指标。

临床怎么用

  • 可考虑采用平台试验设计,将多种治疗与共同对照药比较,以服务患者、家庭和卫生服务体系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic non-bacterial osteomyelitis (CNO) is an autoinflammatory bone disease primarily affecting children and adolescents. The condition is characterised by bone pain, hyperostosis, and bone deformities, impacting patients' quality of life. Although CNO is the second most common inflammatory rheumatic disease in childhood, no licensed treatments exist. Clinical trials have been challenged by the absence of validated classification criteria and inclusion and exclusion criteria, a shortage of well-validated tools to measure treatment response, and a small market for commercialisation. Clinical trials are urgently needed to generate evidence and allow licensing of medications. Since 2022, long-standing challenges, previously hindering trial design and delivery in CNO, have been addressed through the development of classification criteria, expert consensus on inclusion and exclusion criteria, and the development of outcome measures. Applying a platform trial design testing treatments against a common comparator promises to deliver several key benefits for patients with CNO, families, and health-care services. This Viewpoint summarises treatments currently used to treat CNO alongside promising future candidates, outlining challenges in trial design and how these have, partly, been overcome.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Hedrich CM, Roberts E, Inguscio G, et al. Addressing the urgent need for clinical trials in chronic non-bacterial osteomyelitis. Lancet Rheumatol. 2026. PMID: 42608115. doi:10.1016/S2665-9913(26)00156-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。